Status:
COMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates
Lead Sponsor:
University of Alberta
Conditions:
Transplant
Eligibility:
All Genders
18+ years
Brief Summary
Cytomegalovirus (CMV) is the most common viral infection in patients who have undergone a transplant.Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and t...
Detailed Description
Cytomegalovirus (CMV) disease is an important cause of morbidity in solid organ transplantation recipients. Viral reactivation, either of donor origin or endogenous latent virus involves a complex ser...
Eligibility Criteria
Inclusion
- Male or female patients who fulfill the following criteria are eligible for inclusion:
- Age \>=18 years
- Solid Organ Transplant Recipients
- Documented CMV disease or asymptomatic CMV viremia
Exclusion
- Unable to comply with protocol
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 23 2013
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00677482
Start Date
April 1 2008
End Date
September 23 2013
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G-2E1